drugset / Trial / NCT06972212

Pharmacodynamic Study of 100mg Suzegtrigine vs Placebo in Healthy Male Adults

NCT06972212

Phase 0 Completed 20 enrolled Latigo Biotherapeutics
RandomizedCrossoverTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled within-participant crossover study in healthy male participants 18-55 years of age to assess pain tolerance during a cold pressor test. The study will be conducted at a single center in New Zealand.

Timeline

Start
2025-06-04
Primary completion
2025-06-28
Completion
2025-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule 100 mg

Indications

No indication recorded.